{"filing":{"accession_number":"0001628280-26-051240","cik":"0001325618","ticker":"IRMD","company_name":"IRADIMED CORP","form":"8-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"irmd-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1325618/000162828026051240/irmd-20260731.htm"},"events":[{"id":22883,"run_id":20720,"accession_number":"0001628280-26-051240","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"IRADIMED issued a press release on July 31, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing revenue of $20.5 million, GAAP diluted EPS of $0.41, and non-GAAP diluted EPS of $0.46 for Q2 2026, along with reaffirmed full-year 2026 guidance and a declared quarterly cash dividend of $0.20 per share. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","company_name":"IRADIMED CORP","ticker":"IRMD","filing_date":"2026-07-31","form":"8-K","submitted_at":null,"items":[{"id":22975,"accession_number":"0001628280-26-051240","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"IRADIMED issued a press release on July 31, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing revenue of $20.5 million, GAAP diluted EPS of $0.41, and non-GAAP diluted EPS of $0.46 for Q2 2026, along with reaffirmed full-year 2026 guidance and a declared quarterly cash dividend of $0.20 per share. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:37:12.910445+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22975,"accession_number":"0001628280-26-051240","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"IRADIMED issued a press release on July 31, 2026 announcing financial results for the quarter ended June 30, 2026, disclosing revenue of $20.5 million, GAAP diluted EPS of $0.41, and non-GAAP diluted EPS of $0.46 for Q2 2026, along with reaffirmed full-year 2026 guidance and a declared quarterly cash dividend of $0.20 per share. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:37:12.910445+00:00","company_name":"IRADIMED CORP","ticker":"IRMD","filing_date":"2026-07-31"}]}